Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01524666

Enrollment

Registered

2012-02-02

Start date

2012-02-29

Completion date

2018-10-31

Last updated

2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Neuropathy

Brief summary

This is a nonblinded Case-only study that evaluates the effects of Agmatine Sulfate on small fiber peripheral neuropathy. Patients will be started on Agmatine sulfate (a metabolite of Arginine) and monitored for two months. Improvement will be noted on their response to the Neuropathic Pain Questionnaire. Additionally the investigators will note improvement by performing autonomic function testing at the beginning and end of the study.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Men and Women Ages 18-75 with symptoms of small Fiber Neuropathy and have been diagnosed via autonomic function testing and or skin biopsy

Exclusion criteria

* Women who are pregnant or breast feeding, patients with history of substance abuse, and patients with myelopathy

Design outcomes

Primary

Measure	Time frame
Neuropathic Pain Questionnaire	After 2 months

Secondary

Measure	Time frame
QSART & ANSAR testing	After 2 months

Countries

United States

Contacts

Primary ContactMichael Rosenberg, MD

mrosenberg@jfkhealth.org732-321-7010

Outcome results